{"id":4333,"date":"2019-02-28T14:54:41","date_gmt":"2019-02-28T09:24:41","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=4333"},"modified":"2023-06-14T09:29:59","modified_gmt":"2023-06-14T03:59:59","slug":"business-cocktail-gene-therapies","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-gene-therapies","title":{"rendered":"The Business Cocktail"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69fd0614ee446\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69fd0614ee446\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-gene-therapies\/#Cell_Medica_receives_funds_for_its_cell_therapy\" >Cell Medica receives funds for its cell therapy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-gene-therapies\/#Blackstone_Life_Sciences_invests_USD_250_million_along_with_Novartis_forms_a_new_Biotech_Anthos\" >Blackstone Life Sciences\ninvests USD 250 million along with Novartis forms a new Biotech Anthos<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-gene-therapies\/#Ultragenyx_lists_USD_3043_million_Public_Offering\" >Ultragenyx lists USD 304.3\nmillion Public Offering<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-gene-therapies\/#Spark_Therapeutics_merges_with_ROCHE_both_financially_and_medically\" >Spark Therapeutics merges\nwith ROCHE, both financially and medically<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-gene-therapies\/#Sarepta_buys_Myonexus_for_USD_165_Million\" >Sarepta buys Myonexus for USD 165 Million<\/a><\/li><\/ul><\/nav><\/div>\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Cell_Medica_receives_funds_for_its_cell_therapy\"><\/span><strong>Cell Medica<\/strong> <strong>receives funds for its cell therapy<\/strong> <span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background\" style=\"background-color:#e0d9ca\">A <strong>USD 8.7 million<\/strong> grant to <strong>Cell Medica<\/strong> has been given by <strong>Cancer Prevention and Research Institute of Texas<\/strong> (<strong>CPRIT<\/strong>) to speed up the clinical development of <strong>CMD-502<\/strong> <strong>off-the-shelf chimeric antigen receptor-natural killer T cell<\/strong> (CAR-NKT) cell therapy. The program, supported by <strong>Baylor College of Medicine<\/strong> (BCM), aims to offer a simplified manufacturing way to be able to treat a large number of patients. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Blackstone_Life_Sciences_invests_USD_250_million_along_with_Novartis_forms_a_new_Biotech_Anthos\"><\/span><strong>Blackstone Life Sciences\ninvests USD 250 million along with Novartis forms a new Biotech Anthos<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background\" style=\"background-color:#e0d9ca\"><strong>Anthos Therapeutics<\/strong>, a new leaf in the branch, backed up with <strong>USD 250 million<\/strong> to extend the advancement of <strong>MAA868, <\/strong>a <strong>NOVARTIS<\/strong> antibody drug meant to target <a href=\"https:\/\/www.delveinsight.com\/report-store\/blood-coagulation-factor-activators-pipeline-insight\"><strong>blood clots<\/strong><\/a>. <strong>Blackstone Life Science <\/strong>aims to fund more of such drugs being left behind due to monetary factors. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Ultragenyx_lists_USD_3043_million_Public_Offering\"><\/span><strong>Ultragenyx lists USD 304.3\nmillion Public Offering <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background\" style=\"background-color:#e0d9ca\"><strong>Ultragenyx Pharmaceutical Inc.,<\/strong> a biopharmaceutical company, which focuses on the development of novel products for serious rare and ultra-<strong>rare genetic diseases<\/strong> announced the pricing of its underwritten public offering 5,072,464 shares at <strong>USD 60.00 per share<\/strong> to the public. The offerings will be open for a period of 30 days. <strong>Latham &amp; Watkins LLP<\/strong> here will be the underwriters.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Spark_Therapeutics_merges_with_ROCHE_both_financially_and_medically\"><\/span><strong>Spark Therapeutics merges\nwith ROCHE, both financially and medically<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background\" style=\"background-color:#e0d9ca\">For approximately <strong>USD 4.8 billion, Roche<\/strong> is going to acquire all the outstanding shares of <strong>Spark Therapeutics <\/strong>in an all-cash transaction. Based in Philadelphia, Spark Therapeutics is fully committed to discover and deliver <a href=\"https:\/\/www.delveinsight.com\/blog\/is-gene-therapy-the-next-cancer-treatment-revolution\/\"><strong>gene therapies<\/strong><\/a> for genetic diseases. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Sarepta_buys_Myonexus_for_USD_165_Million\"><\/span><strong>Sarepta buys Myonexus for USD 165 Million<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p class=\"has-background\" style=\"background-color:#e0d9ca\"><strong>Sarepta <\/strong>in the run to fulfill its mission of developing gene therapies to defeat rare<strong> genetic diseases<\/strong> has gone ahead to buy <strong>Myonexus Therapeutics. <\/strong>Together they share a mutual goal to find solutions for <strong>Limb-girdle<a href=\"https:\/\/www.delveinsight.com\/report-store\/duchenne-muscular-dystrophy-market-insight-epidemiology-and-market-forecast\"> muscular dystrophy<\/a>&nbsp;(<\/strong>LGMD) patients.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cell Medica receives funds for its cell therapy A USD 8.7 million grant to Cell Medica has been given by Cancer Prevention and Research Institute of Texas (CPRIT) to speed up the clinical development of CMD-502 off-the-shelf chimeric antigen receptor-natural killer T cell (CAR-NKT) cell therapy. The program, supported by Baylor College of Medicine (BCM), [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4337,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":1,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[2680,2674,258,19344,17691,423,524,626,543,16850],"industry":[17225],"therapeutic_areas":[17235,17238,17233],"class_list":["post-4333","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-blackstone-life-sciences","tag-cell-medica","tag-gene-therapy","tag-limb-girdle-muscular-dystrophy-2","tag-myonexus","tag-novartis","tag-roche","tag-sarepta","tag-spark-therapeutics","tag-ultragenyx","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-genetic-disorders","therapeutic_areas-hematological-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Cell Medica receives funds for its cell therapy | DelveInsight<\/title>\n<meta name=\"description\" content=\"A USD 8.7 million grant to Cell Medica has been given by Cancer Prevention and Research Institute of Texas (CPRIT) to speed up the clinical development..\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-gene-therapies\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cell Medica receives funds for its cell therapy | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"A USD 8.7 million grant to Cell Medica has been given by Cancer Prevention and Research Institute of Texas (CPRIT) to speed up the clinical development..\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-gene-therapies\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-02-28T09:24:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-14T03:59:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/02\/09021651\/business-2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1084\" \/>\n\t<meta property=\"og:image:height\" content=\"782\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cell Medica receives funds for its cell therapy | DelveInsight","description":"A USD 8.7 million grant to Cell Medica has been given by Cancer Prevention and Research Institute of Texas (CPRIT) to speed up the clinical development..","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-gene-therapies","og_locale":"en_US","og_type":"article","og_title":"Cell Medica receives funds for its cell therapy | DelveInsight","og_description":"A USD 8.7 million grant to Cell Medica has been given by Cancer Prevention and Research Institute of Texas (CPRIT) to speed up the clinical development..","og_url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-gene-therapies","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-02-28T09:24:41+00:00","article_modified_time":"2023-06-14T03:59:59+00:00","og_image":[{"width":1084,"height":782,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/02\/09021651\/business-2.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-gene-therapies","url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-gene-therapies","name":"Cell Medica receives funds for its cell therapy | DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-gene-therapies#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-gene-therapies#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/02\/09021651\/business-2.png","datePublished":"2019-02-28T09:24:41+00:00","dateModified":"2023-06-14T03:59:59+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"A USD 8.7 million grant to Cell Medica has been given by Cancer Prevention and Research Institute of Texas (CPRIT) to speed up the clinical development..","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/business-cocktail-gene-therapies"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-gene-therapies#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/02\/09021651\/business-2.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/02\/09021651\/business-2.png","width":1084,"height":782},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/02\/09021651\/business-2-300x216.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Blackstone Life Sciences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cell Medica<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gene therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Limb Girdle Muscular Dystrophy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Myonexus<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novartis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Roche<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sarepta<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Spark therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ultragenyx<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Blackstone Life Sciences<\/span>","<span class=\"advgb-post-tax-term\">Cell Medica<\/span>","<span class=\"advgb-post-tax-term\">Gene therapy<\/span>","<span class=\"advgb-post-tax-term\">Limb Girdle Muscular Dystrophy<\/span>","<span class=\"advgb-post-tax-term\">Myonexus<\/span>","<span class=\"advgb-post-tax-term\">Novartis<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>","<span class=\"advgb-post-tax-term\">Sarepta<\/span>","<span class=\"advgb-post-tax-term\">Spark therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Ultragenyx<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Feb 28, 2019","modified":"Updated on Jun 14, 2023"},"absolute_dates_time":{"created":"Posted on Feb 28, 2019 2:54 pm","modified":"Updated on Jun 14, 2023 9:29 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4333","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=4333"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4333\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/4337"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=4333"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=4333"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=4333"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=4333"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=4333"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}